TY - JOUR
T1 - The interleukin-8 (IL-8/CXCL8) receptor inhibitor reparixin improves neurological deficits and reduces long-term inflammation in permanent and transient cerebral ischemia in rats
AU - Villa, Pia
AU - Triulzi, Sara
AU - Cavalieri, Barbara
AU - Di Bitondo, Rosa
AU - Bertini, Riccardo
AU - Barbera, Sara
AU - Bigini, Paolo
AU - Mennini, Tiziana
AU - Gelosa, Paolo
AU - Tremoli, Elena
AU - Sironi, Luigi
AU - Ghezzi, Pietro
PY - 2007/3
Y1 - 2007/3
N2 - Leukocyte infiltration is viewed as a pharmacological target in cerebral ischemia. We previously reported that reparixin, a CXCL8 receptor blocker that inhibits neutrophil infiltration, and related molecules can reduce infarct size in a rat model of transient middle cerebral artery occlusion (MCAO). The study aims were to compare the effects of reparixin in transient and permanent MCAO using varied treatment schedules and therapeutic windows to evaluate effects on long-term neurological deficits and late inflammatory response. Reparixin, administered for 1 to 3 days, 3.5 to 6 h after MCAO, ameliorates neurological function recovery and inhibits long-term inflammation. The infarct size reduction at 24 h, evaluated by TTC staining, is more pronounced in transient MCAO. MRI analysis identified a decrease in the progression of infarct size by reparixin that was more evident at 48 h in permanent MCAO, and was associated with a significantly improved recovery from long-term neurological deficits.
AB - Leukocyte infiltration is viewed as a pharmacological target in cerebral ischemia. We previously reported that reparixin, a CXCL8 receptor blocker that inhibits neutrophil infiltration, and related molecules can reduce infarct size in a rat model of transient middle cerebral artery occlusion (MCAO). The study aims were to compare the effects of reparixin in transient and permanent MCAO using varied treatment schedules and therapeutic windows to evaluate effects on long-term neurological deficits and late inflammatory response. Reparixin, administered for 1 to 3 days, 3.5 to 6 h after MCAO, ameliorates neurological function recovery and inhibits long-term inflammation. The infarct size reduction at 24 h, evaluated by TTC staining, is more pronounced in transient MCAO. MRI analysis identified a decrease in the progression of infarct size by reparixin that was more evident at 48 h in permanent MCAO, and was associated with a significantly improved recovery from long-term neurological deficits.
UR - http://www.scopus.com/inward/record.url?scp=34250675226&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250675226&partnerID=8YFLogxK
U2 - 10.2119/2007-00008.Villa
DO - 10.2119/2007-00008.Villa
M3 - Article
C2 - 17592546
AN - SCOPUS:34250675226
VL - 13
SP - 125
EP - 133
JO - Molecular Medicine
JF - Molecular Medicine
SN - 1076-1551
IS - 3-4
ER -